Delivery Order SPE2DB20D1100-SPE2DB24FA2A7
- Not listed
- This is a federal contract award made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML, a pharmaceutical product, with a ceiling value of $2,526.54 and a period of performance ending on March 17, 2025. The contract is a Delivery Order with a Firm Fixed Price pricing type and does not have a set-aside designation, indicating open...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The $1,242.60 firm fixed price delivery order is for the supply of HEMANGEOL 4.28 MG/ML oral solution in 120 mL units, with a completion date of January 29, 2024. Amerisourcebergen Drug Corp is a prime contractor that has received numerous federal contract awards from DLA...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, the Corporate Office division of Amerisourcebergen Corporation, a major pharmaceutical distribution company. The $1,656.80 firm fixed price contract is for the supply of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML, a pharmaceutical product. The contract has a completion date of May 8, 2024 and does not have a set-aside designation. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract...
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML. The $1,684.36 contract has a period of performance through July 29, 2025. This award is not designated as a set-aside contract. AmerisourceBergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a comprehensive global...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an award value of $1,263.27 and is for the delivery of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML, a pharmaceutical product. The contract has an ultimate completion date of February 24, 2025 and is a firm fixed price delivery order. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $1,656.80 to Amerisourcebergen Drug Corp, a subsidiary of the for-profit company Cencora, Inc. doing business as Amerisourcebergen. The contract is for the delivery of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML, a pharmaceutical product, with a completion date of March 26, 2024. This award is associated with a larger indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA, valued at up...
- This is a $2,526.54 firm fixed-price delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the delivery of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML, a pharmaceutical product. This contract is not set aside and has a period of performance through July 31, 2025. Amerisourcebergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated as...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,775.04 to supply Hemangeol 4.28 mg/ml oral solution (120ml) with a completion date of January 6, 2026. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- This federal contract award to Amerisourcebergen Drug Corporation's Corporate Office Division is for the delivery of the pharmaceutical product HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML to the Defense Logistics Agency (DLA). The contract, valued at $2,485.20, is a Firm Fixed Price Delivery Order with a completion date of July 26, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025,...
- This is a delivery order awarded to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, by the Defense Logistics Agency (DLA). The order is for the pharmaceutical product HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML, with a ceiling value of $1,656.80 and a period of performance through May 21, 2024. Amerisourcebergen Drug Corp is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, including the Department of Defense (DoD) and...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB24FA2A7Delivery Order
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the supply of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML, a pharmaceutical product, with a potential value of $1,242.60 and a completion date of March 5, 2024. Amerisourcebergen Drug Corp, through its Corporate Office division located in Conshohocken, Pennsylvania, is the prime contractor on this award. The contract does not have a set-aside designation. Amerisourcebergen Drug Corp is also the prime contractor on a larger indefinite delivery contract (IDC) with DLA, valued at up to $999,999,999.00, to provide a comprehensive range of pharmaceutical products and medical supplies to support the Department of Defense's military treatment programs and facilities worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 2/12/24 |